Emma Guttman

Search results

• Studies from Icahn School of Medicine at Mount Sinai Provide New Data on Antidepressants (Immune-targeted Therapies for Depression: Current Evidence for Antidepressant Effects of Monoclonal Antibodies)

  Cathomas, F., Rizk, M., Murrough, J., Russo, S. & Guttman, E.

  3/09/24

  1 item of Media coverage

  Press/Media

• Studies from Icahn School of Medicine at Mount Sinai in the Area of Atopic Dermatitis Described (628 - Clinical measures of improvement in atopic dermatitis are correlated with reductions in relevant biomarkers in patients treated with ...)

  Guttman, E.

  23/08/24

  1 item of Media coverage

  Press/Media

• Research Findings from Icahn School of Medicine at Mount Sinai Update Understanding of Atopic Dermatitis (The role of OX40 ligand/OX40 axis signalling in atopic dermatitis)

  Guttman, E.

  20/08/24

  1 item of Media coverage

  Press/Media

• Dupilumab Shows Promising Results for Hair Regrowth in Pediatric Alopecia Areata, with No New Safety Concerns: Study

  Guttman, E.

  17/08/24

  1 item of Media coverage

  Press/Media

• Investigators from Icahn School of Medicine at Mount Sinai Target Alopecia (Dupilumab Induces Hair Regrowth In Pediatric Alopecia Areata: a Real-world, Single-center Observational Study)

  Guttman, E. & Ungar, B.

  16/08/24

  1 item of Media coverage

  Press/Media

• Tralokinumab treatment may neutralize IL-13 in patients with atopic dermatitis

  Guttman, E.

  12/08/24

  1 item of Media coverage

  Press/Media

• Top news of July: Anaphylaxis guidelines, epinephrine, FDA applications, more

  Chehade, M. & Guttman, E.

  1/08/24

  1 item of Media coverage

  Press/Media

• Novel Pan-JAK Inhibitor Cream Improves Chronic Hand Eczema Symptoms

  Guttman, E.

  23/07/24

  1 item of Media coverage

  Press/Media

• Arcutis Biotherapeutics soars 232% in 2024, outperforming 99% of its global peers

  Guttman, E. & Ungar, B.

  12/07/24

  1 item of Media coverage

  Press/Media

• Mount Sinai Secures Over $4 Million Grant From National Institutes of Health to Study Alopecia Areata and Atopic Dermatitis in People With Down Syndrome

  Guttman, E.

  12/07/24

  1 item of Media coverage

  Press/Media

• Mount Sinai Wins $4M NIH Grant to Study Alopecia, Dermatitis

  Guttman, E.

  12/07/24

  1 item of Media coverage

  Press/Media

• Mount Sinai secures over $4 million grant from National Institutes of Health to study alopecia areata and atopic dermatitis in people with Down Syndrome

  Guttman, E.

  11/07/24

  3 items of Media coverage

  Press/Media

• Mount Sinai Secures Over $4 Million Grant From National Institutes of Health to Study Alopecia Areata and Atopic Dermatitis in People With Down Syndrome

  Guttman, E.

  11/07/24

  1 item of Media coverage

  Press/Media

• Monthly: Arcutis Biotherapeutics (ARQT: $9.30) gains 11%, beating 99% of stocks

  Guttman, E. & Ungar, B.

  1/07/24

  1 item of Media coverage

  Press/Media

• Monthly: Arcutis Biotherapeutics (ARQT: $9.30) up 11%, beating 99% of stocks

  Guttman, E. & Ungar, B.

  28/06/24

  1 item of Media coverage

  Press/Media

• Arcutis Biotherapeutics continues uptrend, soars 189% and in top 2% of the market

  Guttman, E. & Ungar, B.

  14/06/24

  1 item of Media coverage

  Press/Media

• US SECTOR WEEKLY: PRESS RELEASES OF LISTED COMPANIES IN THE HEALTH CARE SECTOR FRIDAY JUNE 14, 2024

  Guttman, E.

  14/06/24

  1 item of Media coverage

  Press/Media

• US SECTOR DAILY: PRESS RELEASES OF LISTED COMPANIES IN THE HEALTH CARE SECTOR TUESDAY JUNE 11, 2024

  Guttman, E.

  11/06/24

  1 item of Media coverage

  Press/Media

• US SECTOR DAILY: PRESS RELEASES OF LISTED COMPANIES IN THE STOCK SNIPPETS - ESG TUESDAY JUNE 11, 2024

  Guttman, E.

  11/06/24

  1 item of Media coverage

  Press/Media

• Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

  Guttman, E.

  10/06/24

  99 items of Media coverage

  Press/Media

• Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

  Guttman, E.

  10/06/24

  1 item of Media coverage

  Press/Media

• Arcutis Announces New Long-Term Data Of Roflumilast Cream 0.15% For The Treatment Of Mild To Moderate Atopic Dermatitis (AD) In Adults And Children Down To Age Six Presented At Revolutionizing Alopecia Areata, Vitiligo, And Eczema Conference

  Guttman, E.

  10/06/24

  1 item of Media coverage

  Press/Media

• Mount Sinai Health System: Emma Guttman-Yassky, MD, PhD, Receives High Honor at European Academy of Allergy and Clinical Immunology

  Guttman, E.

  4/06/24

  1 item of Media coverage

  Press/Media

• Emma Guttman-Yassky, MD, Ph.D., receives high honor at European Academy of Allergy and Clinical Immunology The Paul Ehrlich Award for Experimental Research recognizes scientists who have revolutionized the understanding of allergic diseases and immunologi

  Guttman, E.

  4/06/24

  1 item of Media coverage

  Press/Media

• Emma Guttman-Yassky, MD, PhD, Receives High Honor at European Academy of Allergy and Clinical Immunology

  Guttman, E.

  4/06/24

  1 item of Media coverage

  Press/Media